Clinical Trials Logo
  1. Home
  2. Arthritis, Juvenile Rheumatoid
  3. NCT00688545

Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis — SINCERE  

Arthritis, Juvenile Rheumatoid Clinical Trial

Official title:
SINCERE™: Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry A Prospective Observational Registry Of Patients With Juvenile Idiopathic Arthritis (JIA) Treated With NSAIDs

Clinical Trial Summary

This multi-center observational Registry will collect long-term safety data on patients treated with celecoxib or non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) as used in clinical practice for the treatment of Juvenile Idiopathic Arthritis (JIA).

Clinical Trial Description

None Study has been terminated early (LSLV = 09Jan2012) due to release of the postmarketing commitment by the US FDA. The study was stopped for futility/change in treatment paradigm that minimizes chronic NSAID use and not for safety concerns. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00688545
Study type Observational
Source Pfizer
Contact
Status Terminated
Phase
Start date April 2009
Completion date January 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT00807846 - A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects Phase 4
Completed NCT00279747 - A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) Phase 3
Completed NCT00652925 - A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Phase 3
Completed NCT02001844 - Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA N/A
Completed NCT00731965 - Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Phase 4
Completed NCT02067962 - Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing N/A
Terminated NCT00868751 - Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis N/A
Terminated NCT00637780 - Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis Phase 4
Completed NCT00001614 - The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis Phase 1
Completed NCT01412021 - Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
Enrolling by invitation NCT02377245 - Juvenile Inflammatory Rheumatism (JIR) Cohorte
Completed NCT00426218 - Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Phase 1/Phase 2
Completed NCT00034853 - Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) Phase 3
Recruiting NCT06000566 - Drug Compliance and Affecting Factors in Juvenile Idiopathic Arthritis
Terminated NCT00511329 - Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease Phase 2/Phase 3
Recruiting NCT00012506 - The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Phase 3